Sionna Therapeutics (NASDAQ:SION) Shares Gap Down – Here’s What Happened

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) gapped down before the market opened on Monday . The stock had previously closed at $36.54, but opened at $32.89. Sionna Therapeutics shares last traded at $33.53, with a volume of 21,404 shares.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SION shares. Guggenheim raised their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup started coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They issued an “outperform” rating for the company. BTIG Research restated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research note on Monday. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.57.

Sionna Therapeutics Price Performance

The business’s 50 day simple moving average is $39.42 and its 200 day simple moving average is $35.31. The stock has a market cap of $1.52 billion and a P/E ratio of -17.48.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.15.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 29,063 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the sale, the director owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. This represents a 0.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the sale, the insider owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This trade represents a 3.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 382,368 shares of company stock worth $15,898,607 over the last three months. Company insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. grew its position in Sionna Therapeutics by 114.6% during the 2nd quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock worth $2,345,000 after acquiring an additional 72,185 shares during the last quarter. Braidwell LP acquired a new position in Sionna Therapeutics in the second quarter worth $18,770,000. Bosun Asset Management LLC acquired a new position in Sionna Therapeutics in the second quarter worth $295,000. JPMorgan Chase & Co. grew its holdings in shares of Sionna Therapeutics by 2.4% during the second quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at $45,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.